The potential benefits of using other tumor-specific promoters in melanoma therapy were assessed by determining the activity of the luciferase reporter gene, when it is transcriptionally controlled by promoters of the Cox-2, CXCR4 , and BIRC5  genes. The gene discussed is BIRC5; the disease is neoplasm.